H-1B Filings
21
Major sponsor. DOL labor condition applications on file.
Tris Pharma, Inc. in NJ (Manufacturing) is a sponsorship-and-safety profile: 21 H-1B LCAs plus an employer-specific OSHA injury record, with no WARN notices in this corpus.
Tris Pharma, Inc. (NJ): · 21 H-1B LCAs at a $97,739 disclosed median · OSHA Grade C (DART 1.12)
According to DOL OFLC H-1B disclosures, OSHA ITA injury logs, and state WARN Act notices, Tris Pharma, Inc. in NJ carries 21 H-1B wage filings on record, a $97,739 median wage across 16 disclosed-wage positions (below the $124,488 national median), a middling C OSHA safety grade and no WARN layoff notices on file. Every figure is a federal filing, not an estimate; see methodology for coverage limits.
The record at a glance
Compared with the rest of PlainEmployers' federal employer corpus, H-1B filing volume ranks #2,451 of 51,370 sponsors in this corpus (about the 95th percentile), and disclosed median wage sits at the 26th percentile of 272,125 credible H-1B wage rows.
Figures above come from DOL H-1B LCAs and this employer's OSHA injury log; no WARN notices are on file here.
A weighted composite of DOL H-1B sponsorship and pay, OSHA establishment injury records, and WARN Act layoff notices, not culture, benefits, or "is this a good place to work." Missing tracks drop out and their weight redistributes so sparse records are not silently deflated.
Weights (redistributed when a track is N/A): Sponsorship scale (H-1B volume) 15% · Disclosed pay (H-1B wage percentile) 25% · Workplace safety (OSHA DART percentile) 35% · Layoff stability (WARN percentile) 25%. Sources: DOL OFLC · OSHA ITA · state WARN filings.
DOL LCA release change
H-1B Filings
21
Major sponsor. DOL labor condition applications on file.
Median H-1B Salary
$97,739
Below national median. Across 16 disclosed positions
OSHA Safety Grade
Grade C · DART 1.12
Near industry average. vs 1.14 same 2-digit NAICS sector (OSHA ITA 2022–2023, hours-weighted)
Where Tris Pharma, Inc.'s H-1B wage sits nationally
Median disclosed wage vs. all US employers with H-1B filings
$97,739 Top 74% higher than 26% of 272,125 US employers
Each bar is a $20K-wide band; taller bars hold more US employers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source DOL Office of Foreign Labor Certification, H-1B Disclosure Data · August 2026
Filing-count-weighted median across this employer's own disclosed H-1B positions (-19.1% year over year), not a company-wide raise, and not adjusted for role mix changes between years.
| Field | Value | Source |
|---|---|---|
| Employer Name | Tris Pharma, Inc. | DOL OFLC / OSHA |
| Industry | Manufacturing | NAICS / DOL |
| State | NJ | U.S. Federal Records |
| H-1B Filings | 21 | DOL OFLC LCA Disclosure |
| H-1B Median Salary | $97,739 | DOL OFLC LCA Disclosure |
| OSHA Safety Grade | C | OSHA ITA |
| OSHA DART Rate | 1.12 | OSHA ITA Establishment Records |
| Tracks not on file | WARN notices | Empty by design, not estimated |
Tris Pharma, Inc.'s values above reflect the most recent DOL Labor Condition Applications, OSHA Injury Tracking Application records on file for this employer in NJ (Manufacturing). In this corpus, H-1B filing volume ranks #2,451 of 51,370 sponsors in this corpus (about the 95th percentile); disclosed median wage sits at the 26th percentile of 272,125 credible H-1B wage rows; OSHA DART rate is safer than roughly 51% of 214,554 employers with an establishment injury record.
| Job Title | Median |
|---|---|
| Director, Drug Safety | $237,453 |
| Network Engineer | $174,440 |
| Method Validation Scientist III | $115,648 |
| Senior Scientist I (Product Development) | $114,483 |
| Packaging Component Engineer | $99,433 |
| Project Manager | $98,363 |
| Method Validation Scientist III | $98,134 |
| Pharmaceutical Development Scientist II | $97,739 |
| Method Validation Scientist II | $93,745 |
| Qualification Engineer | $91,894 |
| Analytical Research and Development Scientist I | $91,362 |
| Method Validation Scientist I | $80,600 |
| QC Lab Operation Chemist | $80,600 |
| Sr. Specialist, Regulatory Affairs CMC | $77,667 |
| QC Analytical Chemist I | $72,770 |
| QC Analytical Chemist I | $63,086 |
Momentum is the headline: FY2025 filings (11) rose 120% from FY2024 (5), one of the sharper year-over-year jumps in the corpus.
Tris Pharma, Inc. in NJ (Manufacturing) filed 21 H-1B labor condition applications, of which 16 disclose a usable wage figure at a $97,739 disclosed median — a top-tercile sponsorship footprint in this corpus.
Disclosed medians moved from $117,150 (FY2024) to $94,785 (FY2025) (-19.1%), weighted by this employer's own LCA rows — not a company-wide raise and not role-mix adjusted.
No WARN Act mass-layoff notices are on file for Tris Pharma, Inc. among Manufacturing employers we track.
Disclosed pay runs low: $97,739 median trails 74% of wage rows and sits under the $124,488 national median.
DART 1.1 tracks close to the 1.1 sector average (Grade C).
Tris Pharma, Inc.'s DART rate (days away/restricted/transferred per 100 FTE) vs the hours-weighted 2-digit NAICS sector average from OSHA ITA 2022–2023 (Manufacturing).
Total reported injuries on file: 16.
Where Tris Pharma, Inc. sits
Across the 200 Manufacturing sponsors in this corpus with both an H-1B filing count and a credible disclosed-wage median, Tris Pharma, Inc. files more petitions than 3% of them and discloses a higher median wage than 2%, the selective, below-median pay quadrant. Filing volume is hiring scale, not pay; the axes are independent DOL OFLC disclosures (21 filings · $97,739 median here).
Each muted dot is one manufacturing peer from a filings-stratified sample of 42; the brand marker is Tris Pharma, Inc.. Source: DOL Office of Foreign Labor Certification H-1B LCA disclosures (credible wages recomputed from per-position filings, excluding parse errors above $500k).
Tris Pharma, Inc.'s nearest H-1B-filing peers in Manufacturing (home state NJ). Each card links to that employer's federal-records profile.
Two federal-records peer sets for Tris Pharma, Inc., both outside NJ so the neighborhoods are not the same-industry VsCard above.
Nearest injury-rate peers outside NJ (DART 1.12 here).
Peers are nearest-neighbor matches on disclosed filing counts and OSHA ITA DART rates; employers with fewer than 100 H-1B filings or fewer than 10 reported injuries are excluded from the comparison corpus.
What to check before working with Tris Pharma, Inc.
For Tris Pharma, Inc., read sponsorship pay (21 H-1B LCAs, median $97,739) next to the OSHA safety grade (C).
Tris Pharma, Inc.'s figures are legally filed public records (DOL, OSHA, state WARN), not reviews or vendor estimates; a missing row is not proof the underlying activity never happened.
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from OSHA and the DOL Wage and Hour Division. Consult a qualified professional before making decisions based on this data.
Among 272,125 credible H-1B wage rows in this corpus, Tris Pharma, Inc.'s disclosed median of $97,739 sits at the 26th percentile (below the $124,488 national median). The chart above uses a COUNT-exact percentile (rows below this wage ÷ total), not an interpolated estimate.
Tris Pharma, Inc. has 21 H-1B filings on record, ranking #2,451 of 51,370 sponsors in this corpus (about the 95th percentile by volume). Filing volume is a sponsorship signal, not a headcount or hiring-quality score.
Tris Pharma, Inc. carries Grade C from its establishment injury record (16 injuries on file; DART 1.12). That DART rate is safer than roughly 51% of 214,554 employers with an injury record in this corpus. Grades compare DART against industry averages, see the Interpreting Safety Grades guide.
Related guides: How OSHA safety grades are calculated · Using H-1B wage filings in salary negotiation
Read our methodology - how this data is sourced, computed, and verified.
This profile is rendered directly from DOL H-1B disclosure filings and OSHA Injury Tracking Application records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.